Large Molecule Patents
Humira is a drug owned by Abbvie Inc.. It is protect by 66 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9550826 | ABBVIE INC. | Glycoengineered binding protein compositions |
Nov, 2034
(10 years from now) | Active |
| US9499614 | ABBVIE INC. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
Mar, 2034
(9 years from now) | Active |
| US9150645 | ABBVIE INC. | Cell culture methods to reduce acidic species |
May, 2033
(8 years from now) | Active |
| US9266949 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
May, 2033
(8 years from now) | Active |
| US9315574 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Apr, 2033
(8 years from now) | Active |
| US9085618 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | Active |
| US9181337 | ABBVIE INC. | Modulated lysine variant species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | Active |
| US9181572 | ABBVIE INC. | Methods to modulate lysine variant distribution |
Mar, 2033
(8 years from now) | Active |
| US9290568 | ABBVIE INC. | Methods to control protein heterogeneity |
Mar, 2033
(8 years from now) | Active |
| US9334319 | ABBVIE INC. | Low acidic species compositions |
Mar, 2033
(8 years from now) | Active |
| US9346879 | ABBVIE INC. | Protein purification methods to reduce acidic species |
Mar, 2033
(8 years from now) | Active |
| US9359434 | ABBVIE INC. | Cell culture methods to reduce acidic species |
Mar, 2033
(8 years from now) | Active |
| US9499616 | ABBVIE INC. | Modulated lysine variant species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | Active |
| US9708400 | ABBVIE INC. | Methods to modulate lysine variant distribution |
Mar, 2033
(8 years from now) | Active |
| US9062106 | ABBVIE INC. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
Apr, 2032
(7 years from now) | Active |
| US9090688 | ABBVIE INC. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
Apr, 2032
(7 years from now) | Active |
| US9505834 | ABBVIE INC. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
Apr, 2032
(7 years from now) | Active |
| US9522953 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Apr, 2032
(7 years from now) | Active |
| US9683033 | ABBVIE INC. | Cell culture methods to reduce acidic species |
Apr, 2032
(7 years from now) | Active |
| US9957318 | ABBVIE INC. | Protein purification methods to reduce acidic species |
Apr, 2032
(7 years from now) | Active |
| US8708968 | ABBVIE INC. | Removal of needle shields from syringes and automatic injection devices |
Jan, 2032
(7 years from now) | Active |
| US9339610 | ABBVIE INC. | Removal of needle shield from syringes and automatic injection devices |
Jan, 2032
(7 years from now) | Active |
| US9624295 | ABBVIE INC. | Uses and compositions for treatment of psoriatic arthritis |
Mar, 2031
(6 years from now) | Active |
| US8999337 | ABBVIE INC. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
Feb, 2031
(6 years from now) | Active |
| US8420081 | ABBVIE INC. | Antibody formulations and methods of making same |
Jan, 2030
(5 years from now) | Active |
| US11167030 | ABBVIE INC. | Protein formulations and methods of making same |
Nov, 2028
(4 years from now) | Active |
| US11191834 | ABBVIE INC. | Protein formulations and methods of making same |
Nov, 2028
(4 years from now) | Active |
| US9085619 | ABBVIE INC. | Anti-TNF antibody formulations |
Nov, 2028
(4 years from now) | Active |
| US9284370 | ABBVIE INC. | Methods for treating juvenile idiopathic arthritis |
Jun, 2028
(3 years from now) | Active |
| US9669093 | ABBVIE INC. | Methods for treating juvenile idiopathic arthritis |
Jun, 2028
(3 years from now) | Active |
| US8889136 | ABBVIE INC. | Multiple-variable dose regimen for treating TNFα-related disorders |
Oct, 2027
(2 years from now) | Active |
| US8663945 | ABBVIE INC. | Methods of producing anti-TNF-alpha antibodies in mammalian cell culture |
Sep, 2027
(2 years from now) | Active |
| US8906646 | ABBVIE INC. | Fed-batch method of making human anti-TNF-alpha antibody |
Sep, 2027
(2 years from now) | Active |
| US8911964 | ABBVIE INC. | Fed-batch method of making human anti-TNF-alpha antibody |
Sep, 2027
(2 years from now) | Active |
| US9090867 | ABBVIE INC. | Fed-batch method of making anti-TNF-alpha antibody |
Sep, 2027
(2 years from now) | Active |
| US9234032 | ABBVIE INC. | Fed-batch methods for producing adalimumab |
Sep, 2027
(2 years from now) | Active |
| US9284371 | ABBVIE INC. | Methods of producing adalimumab |
Sep, 2027
(2 years from now) | Active |
| US8715664 | ABBVIE INC. | Use of human TNFα antibodies for treatment of erosive polyarthritis |
Jul, 2027
(2 years from now) | Active |
| US8926975 | ABBVIE INC. | Method of treating ankylosing spondylitis |
Jun, 2027
(2 years from now) | Active |
| US11083792 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US8231876 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US8883156 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US8895009 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US8906372 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US8916153 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US9096666 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US9102723 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US9273132 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US9328165 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US9913902 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | Active |
| US8808700 | ABBVIE INC. | Use of TNF alpha inhibitor for treatment of erosive polyarthritis |
May, 2026
(1 year, 5 months from now) | Active |
| US8961973 | ABBVIE INC. | Multiple-variable dose regimen for treating TNFα-related disorders |
Apr, 2025
(4 months from now) | Active |
| US8961974 | ABBVIE INC. | Multiple-variable dose regimen for treating TNFα-related disorders |
Apr, 2025
(4 months from now) | Active |
| US8986693 | ABBVIE INC. | Use of TNFα inhibitor for treatment of psoriasis |
Apr, 2025
(4 months from now) | Active |
| US9061005 | ABBVIE INC. | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease |
Apr, 2025
(4 months from now) | Active |
| US9187559 | ABBVIE INC. | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease |
Apr, 2025
(4 months from now) | Active |
| US9512216 | ABBVIE INC. | Use of TNFα inhibitor |
Apr, 2025
(4 months from now) | Active |
| US8906373 | ABBVIE INC. | Use of TNF-alpha inhibitor for treatment of psoriasis |
Jul, 2023
(1 year, 3 months ago) |
Expired |
| US9067992 | ABBVIE INC. | Use of TNFα inhibitor for treatment of psoriatic arthritis |
Jul, 2023
(1 year, 3 months ago) |
Expired |
| US9085620 | ABBVIE INC. | Use of TNFα inhibitor for treatment of psoriatic arthritis |
Jul, 2023
(1 year, 3 months ago) |
Expired |
| US9090689 | ABBVIE INC. | Use of TNFα inhibitor for treatment of psoriasis |
Jul, 2023
(1 year, 3 months ago) |
Expired |
| US6805686 | ABBVIE INC. | Autoinjector with extendable needle protector shroud |
May, 2023
(1 year, 6 months ago) |
Expired |
| US8911737 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(2 years ago) |
Expired |
| US8974790 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(2 years ago) |
Expired |
| US8992926 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(2 years ago) |
Expired |
| US9546212 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(2 years ago) |
Expired |
Humira's Family Patents
Explore Our Curated Drug Screens
About Humira
Active Ingredients:
Approval Date:
Dosage:
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG/0.8ML | Injection | Rx | Subcutaneous |
| 80MG/0.8ML | Injection | Rx | Subcutaneous |
| 80MG/0.8ML | Injection | Rx | Subcutaneous |
| 20MG/0.4ML | Injection | Rx | Subcutaneous |
| 40MG/0.4ML | Injection | Rx | Subcutaneous |
| 20MG/0.2ML | Injection | Rx | Subcutaneous |
| 20MG/0.4ML | Injection | Disc | Subcutaneous |
| 40MG/0.4ML | Injection | Rx | Subcutaneous |
| 20MG/0.2ML | Injection | Rx | Subcutaneous |
| 20MG/0.4ML | Injection | Disc | Subcutaneous |
| 20MG/0.2ML | Injection | Rx | Subcutaneous |
| 10MG/0.1ML | Injection | Rx | Subcutaneous |
| 80MG/0.8ML | Injection | Rx | Subcutaneous |
| 40MG/0.4ML | Injection | Rx | Subcutaneous |
| 80MG/0.8ML | Injection | Rx | Subcutaneous |
| 10MG/0.2ML | Injection | Disc | Subcutaneous |
| 40MG/0.8ML | Injection | Rx | Subcutaneous |
| 10MG/0.1ML | Injection | Rx | Subcutaneous |
| 10MG/0.2ML | Injection | Disc | Subcutaneous |
| 10MG/0.1ML | Injection | Rx | Subcutaneous |
| 40MG/0.4ML | Injection | Rx | Subcutaneous |
| 20MG/0.4ML | Injection | Disc | Subcutaneous |
| 10MG/0.2ML | Injection | Rx | Subcutaneous |
| 40MG/0.8ML | Injection | Rx | Subcutaneous |
| 10MG/0.2ML | Injection | Disc | Subcutaneous |
| 40MG/0.8ML | Injection | Rx | Subcutaneous |